Autistic disorder therapeutics market set to grow to $5.5 billion by 2018
The autism spectrum disorder (ASD) therapeutics market was valued at $3.1 billion in 2010 and is forecast to grow at a compound annual growth rate (CAGR) of 7.5% over the next eight years to reach $5.5 billion by 2018, finds GlobalData’s new report titled Autistic Disorder Therapeutics.
This market growth is primarily attributed to the high prevalence (0.6% to 1%) and prevalence growth rate (10-17%) of ASD in the US and in certain European countries. Co-morbidities such as anxiety, epilepsy and depression associated with ASD also contribute to the growth of the ASD therapeutics market.
The current competitive landscape consists of two approved drugs, Bristol-Myers Squibb and Otsuka’s Abilify (aripiprazole) and risperidone, for the treatment of irritability associated with autistic disorder; and psychotropic medications such as anti-psychotics, anti-depressants, anti-convulsants and stimulants which are prescribed off-label.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze